Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) during the Symposium ?Novel Approaches for the Discover

B.K. Keppler

doi:10.5414/cpp43566

Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) during the Symposium ?Novel Approaches for the Discover

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp43566 ◽

2005 ◽

Vol 43 (12) ◽

pp. 566

Author(s):

B.K. Keppler

Keyword(s):

Annual Meeting ◽

Anticancer Drug ◽

European Society ◽

Working Group ◽

Drug Research ◽

Central European ◽

Novel Approaches

Download Full-text

Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research EWIV (CESAR)

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp42631 ◽

2004 ◽

Vol 42 (11) ◽

pp. 631

Author(s):

G. Hartung

Keyword(s):

Annual Meeting ◽

Anticancer Drug ◽

European Society ◽

Working Group ◽

Drug Research ◽

Central European

Download Full-text

Standard Operating Procedures for Clinical Trials of the CESAR Central European Society for Anticancer Drug Research - EWIV

10.1159/isbn.978-3-318-01039-8 ◽

2003 ◽

Cited By ~ 1

Keyword(s):

Clinical Trials ◽

Anticancer Drug ◽

European Society ◽

Drug Research ◽

Standard Operating Procedures ◽

Central European ◽

Standard Operating

Download Full-text

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

Investigational New Drugs ◽

10.1007/s10637-005-1445-z ◽

2005 ◽

Vol 23 (4) ◽

pp. 363-368 ◽

Cited By ~ 4

Author(s):

R.-D. Hofheinz ◽

C. Porta ◽

G. Hartung ◽

A. Santoro ◽

A.-R. Hanauske ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Anticancer Drug ◽

Phase Ii ◽

European Society ◽

Drug Research ◽

Phase Ii Study ◽

Study Group ◽

Central European ◽

Group Trial

Download Full-text

431 Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research — EWIV report

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)80439-7 ◽

2004 ◽

Vol 2 (8) ◽

pp. 129 ◽

Cited By ~ 1

Author(s):

C. Dittrich ◽

M. Gneist ◽

A. Zandvliet ◽

C. Johnston ◽

M. Yule

Keyword(s):

Phase I ◽

Anticancer Drug ◽

Pharmacokinetic Study ◽

European Society ◽

Drug Research ◽

Central European

Download Full-text

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

British Journal of Cancer ◽

10.1038/sj.bjc.6604064 ◽

2007 ◽

Vol 97 (11) ◽

pp. 1480-1485 ◽

Cited By ~ 76

Author(s):

S Steinbild ◽

K Mross ◽

A Frost ◽

R Morant ◽

S Gillessen ◽

...

Keyword(s):

Prostate Cancer ◽

Anticancer Drug ◽

Phase Ii ◽

European Society ◽

Drug Research ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Central European ◽

Clinical Phase ◽

Hormone Refractory

Download Full-text

Abstract 1293: A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors: A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)

10.1158/1538-7445.am2011-1293 ◽

2011 ◽

Author(s):

Ralf Axel Hilger ◽

Tobias Wegener ◽

Heike Richly ◽

Georg Ludwig ◽

Klaus Mross ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Anticancer Drug ◽

Dose Escalation ◽

European Society ◽

Drug Research ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Central European

Download Full-text

Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3205 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3205-3205 ◽

Cited By ~ 2

Author(s):

C. Dittrich ◽

A. Hochhaus ◽

S. Schaad ◽

C. Salama ◽

U. Jaehde ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Anticancer Drug ◽

Pharmacokinetic Study ◽

European Society ◽

Drug Research ◽

Central European

Download Full-text

Central European Society for Anticancer Drug Research (CESAR)

Oncology Research and Treatment ◽

10.1159/000027220 ◽

2000 ◽

Vol 23 (5) ◽

pp. 492-493

Author(s):

C. Dittrich ◽

B. Keppler

Keyword(s):

Anticancer Drug ◽

European Society ◽

Drug Research ◽

Central European

Download Full-text

Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp43590 ◽

2005 ◽

Vol 43 (12) ◽

pp. 590-591 ◽

Cited By ~ 40

Author(s):

R.-D. Hofheinz ◽

C. Dittrich ◽

M.A. Jakupec ◽

A. Drescher ◽

U. Jaehde ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Anticancer Drug ◽

European Society ◽

Phase I Study ◽

Drug Research ◽

Central European ◽

Early Results

Download Full-text

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

British Journal of Cancer ◽

10.1038/bjc.2012.257 ◽

2012 ◽

Vol 107 (2) ◽

pp. 280-286 ◽

Cited By ~ 40

Author(s):

K Mross ◽

C Dittrich ◽

W E Aulitzky ◽

D Strumberg ◽

J Schutte ◽

...

Keyword(s):

Anticancer Drug ◽

Phase Ii ◽

European Society ◽

Drug Research ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Collaborative Network ◽

Central European ◽

Adenocarcinoma Of The Pancreas ◽

Bi 2536

Download Full-text

Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) during the Symposium ?Novel Approaches for the Discover

Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research  EWIV (CESAR)

Standard Operating Procedures for Clinical Trials of the CESAR Central European Society for Anticancer Drug Research - EWIV

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

431 Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research — EWIV report

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Abstract 1293: A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors: A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)

Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV

Central European Society for Anticancer Drug Research (CESAR)

Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research EWIV (CESAR)